Literature DB >> 34033890

Role of sex hormones in modulating breast and ovarian cancer associated pain.

Melissa C McHann1, Henry L Blanton1, Josée Guindon2.   

Abstract

According to the National Cancer Institute in 2020 there will be an estimated 21,750 new ovarian cancer cases and 276,480 new breast cancer cases. Both breast and ovarian cancer are hormone dependent cancers, meaning they cannot grow without the presence of hormones. The two most studied hormones in these two cancers are estrogen and progesterone, which are also involved in the modulation of pain. The incidence of pain in breast and ovarian cancer is very high. Research about mechanisms involved in modulation of pain by hormones are still being debated, as some studies find estrogen to be anti-nociceptive and others pro-nociceptive in pain studies. Moreover, analgesic treatments for breast and ovarian cancer-associated pain are limited and often ineffective. In this review, we will focus on estrogen and progesterone mechanisms of action in modulation of pain and cancer. We will also discuss new treatment options for these types of cancer and associated-pain.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast; Cancer; Cannabinoids; Estrogen; Ovarian; Pain; Progesterone

Mesh:

Substances:

Year:  2021        PMID: 34033890      PMCID: PMC8263503          DOI: 10.1016/j.mce.2021.111320

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.369


  112 in total

1.  Rapid CB1 cannabinoid receptor desensitization defines the time course of ERK1/2 MAP kinase signaling.

Authors:  Tanya L Daigle; Christopher S Kearn; Ken Mackie
Journal:  Neuropharmacology       Date:  2007-06-26       Impact factor: 5.250

Review 2.  Chemotherapy-Associated Peripheral Neuropathy in Patients With Early-Stage Breast Cancer: A Systematic Review.

Authors:  Donna R Rivera; Patricia A Ganz; Meghan S Weyrich; Hanna Bandos; Joy Melnikow
Journal:  J Natl Cancer Inst       Date:  2018-02-01       Impact factor: 13.506

3.  Persistent breast pain in post-surgery breast cancer survivors and women with no history of breast surgery or cancer: associations with pain catastrophizing, perceived breast cancer risk, breast cancer worry, and emotional distress.

Authors:  Dana H Bovbjerg; Francis J Keefe; Mary S Soo; Jessica Manculich; Alyssa Van Denburg; Margarita L Zuley; Gretchen M Ahrendt; Celette S Skinner; Sara N Edmond; Rebecca A Shelby
Journal:  Acta Oncol       Date:  2019-02-12       Impact factor: 4.089

Review 4.  Treatment of breast cancer.

Authors:  Karen L Maughan; Mark A Lutterbie; Peter S Ham
Journal:  Am Fam Physician       Date:  2010-06-01       Impact factor: 3.292

5.  Estradiol Acts in Lateral Thalamic Region to Attenuate Varicella Zoster Virus Associated Affective Pain.

Authors:  Crystal Stinson; Shaun M Logan; Larry L Bellinger; Mahesh Rao; Paul R Kinchington; Phillip R Kramer
Journal:  Neuroscience       Date:  2019-07-02       Impact factor: 3.590

6.  Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS).

Authors:  Mark A Ware; Tongtong Wang; Stan Shapiro; Jean-Paul Collet
Journal:  J Pain       Date:  2015-09-16       Impact factor: 5.820

7.  The prevalence and incidence of medicinal cannabis on prescription in The Netherlands.

Authors:  Arno Hazekamp; Eibert R Heerdink
Journal:  Eur J Clin Pharmacol       Date:  2013-04-16       Impact factor: 2.953

8.  Involvement of estrogen in rapid pain modulation in the rat spinal cord.

Authors:  Yan Zhang; Ning Lü; Zhi-Qi Zhao; Yu-Qiu Zhang
Journal:  Neurochem Res       Date:  2012-08-19       Impact factor: 3.996

9.  Estradiol selectively regulates agonist binding sites on the N-methyl-D-aspartate receptor complex in the CA1 region of the hippocampus.

Authors:  N G Weiland
Journal:  Endocrinology       Date:  1992-08       Impact factor: 4.736

10.  Mechanisms of G protein-coupled estrogen receptor-mediated spinal nociception.

Authors:  Elena Deliu; G Cristina Brailoiu; Jeffrey B Arterburn; Tudor I Oprea; Khalid Benamar; Nae J Dun; Eugen Brailoiu
Journal:  J Pain       Date:  2012-08       Impact factor: 5.820

View more
  1 in total

1.  Chronic Administration of Cannabinoid Receptor 2 Agonist (JWH-133) Increases Ectopic Ovarian Tumor Growth and Endocannabinoids (Anandamide and 2-Arachidonoyl Glycerol) Levels in Immunocompromised SCID Female Mice.

Authors:  Henry L Blanton; Melissa C McHann; Haley De Selle; Canice Lei Dancel; Jose-Luis Redondo; Deborah Molehin; Nadezhda A German; Scott Trasti; Kevin Pruitt; Isabel Castro-Piedras; Josée Guindon
Journal:  Front Pharmacol       Date:  2022-02-15       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.